WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA

Saved in:

Bibliographic Details
Main Authors:	NITISH THAKUR, REETESH SHARMA, ANKIT DATA, HARSHA SINGH DANGI, JAY PRAKASH, DARSHAN GONDALIYA, SUNEEL SHARMA
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924030298
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-4503 IMPACT OF RENAL DONATION: AN AMBIDIRECTIONAL STUDY
by: NITISH THAKUR, et al.
Published: (2025-02-01)

WCN25-4547 RENAL TRANSPLANT IN CARDIAC DISEASES: SEEK DIFFICULT BUT MEANINGFUL CHALLENGES
by: Harsha Singh Dangi, et al.
Published: (2025-02-01)

WCN25-4489 ABO & HLA INCOMPATIBLE KIDNEY TRANSPLANT: A SINGLE-CENTER STUDY FROM INDIA
by: Jay Prakash Kumar, et al.
Published: (2025-02-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS
by: Zhaoxin Chen, et al.
Published: (2025-02-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

WCN25-994 RISK FACTORS FOR NODAT - A SINGLE CENTRE STUDY
by: saumya gupta, et al.
Published: (2025-02-01)

WCN25-2185 CAROTID INTIMA MEDIA THICKNESS - IMPROVEMENT IN RENAL TRANSPLANT PATIENTS
by: MOHIT GUPTA, et al.
Published: (2025-02-01)

WCN25-2646 AN UNUSUAL PRESENTATION OF CRESCENTIC GLOMERULONEPHRITIS WITH ANTI GBM ANTIBODY BUT NO GLOMERULAR DEPOSITION
by: Srikant Panda, et al.
Published: (2025-02-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

WCN25-2927 CRESCENTIC GLOMERULONEPHRITIS WITH LIGHT CHAIN DEPOSITION DISEASE – AN ECCENTRIC PRESENTATION OF MULTIPLE MYELOMA
by: RIMA Mahapatra, et al.
Published: (2025-02-01)

WCN24-2269 MODERATE-SEVERE INTRARENAL ARTERIOSCLEROSIS AND CIRCULATING GDF-15 LEVELS MAY INFLUENCE THE CARDIAC-RENAL PROGNOSIS OF IgAN PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation
by: Dingxin Di, et al.
Published: (2023-12-01)

WCN25-1894 CHRONIC KIDNEY DISEASE - MINERAL BONE DISORDER PARAMETERS AND CAROTID INTIMA MEDIA THICKNESS – THEIR CORRELATION IN CHRONIC KIDNEY DISEASE PATIENTS
by: MOHIT GUPTA, et al.
Published: (2025-02-01)

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-4097 A RARE CASE OF ANCA-NEGATIVE PAUCI-IMMUNE CRESCENTIC GLOMERULONEPHRITIS IN AN ADOLESCENT MALE
by: KOUSHIK CHAKMA, et al.
Published: (2025-02-01)

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Durvalumab-Associated Crescentic Glomerulonephritis With IgA Vasculitis-Like Features
by: Tao Zhao, et al.
Published: (2025-07-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN25-1912 HISTOLOGICAL AND BIOLOGICAL CHARACTERIZATION OF A PIG MODEL OF CRESCENTIC GLOMERULONEPHRITIS AND PROTECTIVE EFFECT OF AN ANTAGONIST OF HB-EGF
by: Daniel Gillet, et al.
Published: (2025-02-01)

WCN24-577 STEROID CONTROVERSIES IN THE TREATMENT OF IGANEPHROPATHY: CLINICAL CASE OF RAPID PROGRESSIVE IGAN
by: Olga Chub
Published: (2024-04-01)

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
by: Uptal Patel, et al.
Published: (2025-02-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
by: Radko Komers, et al.
Published: (2024-04-01)

A Case Report of Systemic Lupus Erythematosus With IgA Nephropathy and Crescentic Nephritis
by: Zhifeng Jiang, et al.
Published: (2023-10-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

WCN24-1268 End-Stage Kidney Disease (ESKD) and Chronic Kidney Disease (CKD) Progression among a Hispanic/Latino Population with Primary Immunoglobulin A Nephropathy (IgAN)
by: John Sim, et al.
Published: (2024-04-01)

WCN25-1128 IgA DOMINANT INFECTION RELATED GLOMERULONEPHRITIS
by: Fatima Alkindi, et al.
Published: (2025-02-01)

WCN25-2494 SURPRISINGLY GOOD RESPONSE OF A SEVERE ANCA-NEGATIVE CRESCENTIC PAUCI-IMMUNE GLOMERULONEPHRITIS SUCCESSFULLY TREATED WITH CORTICOSTEROIDS, CYCLOPHOSPHAMIDE AND RITUXIMAB
by: Eleni Theodoropoulou, et al.
Published: (2025-02-01)